# US 2024/0067680 A1 · Synthetic peptide compounds and methods of use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0067680 A1 - Document ID: US20240067680A1 - Status: Published application - Kind: A1 - Application number: 18/480,170 - Filed: 2023-10-03 - Published: 2024-02-29 - Earliest claimed: 2015-06-26 - Assignees: Realta Holdings, LLC - Applicants: Realta Holdings, LLC - Inventors: Neel K. KRISHNA; Kenji CUNNION - Web page: https://patentgrep.com/patent/US20240067680A1 ## CPC - C07K 14/005: from viruses - A61K 38/162: {from virus} - A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol - A61P 7/00: Drugs for disorders of the blood or the extracellular fluid - A61P 25/00: Drugs for disorders of the nervous system - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C12N 2770/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2770/12033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory - C12N 2770/12071: Demonstrated in vivo effect - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions. ## Claims ### Claim at position 1 1-5. (canceled) ### Claim 6 A method of treating a hemolytic reaction in a subject in need thereof comprising: administering to the subject in need thereof a composition comprising a therapeutically effective amount of a synthetic peptide comprising at least about 90% sequence identity to [[an]] at least one amino acid sequence selected from the group consisting of NOs: 5, 6, 7, 8, 11, 12, 21, and 31. ### Claim 7 (depends on 6) The method of claim 6, wherein the method of treating a hemolytic reaction in a subject in need thereof comprises: administering to the subject having a hemolytic reaction a composition comprising a therapeutically effective amount of a synthetic peptide selected from the group consisting of NOs: 5, 6, 7, 8, 11, 12, 21, and 31. ### Claim 8 (depends on 6) The method of claim 6, wherein the hemolytic reaction is selected from the group consisting of acute intravascular hemolytic transfusion reaction (AIHTR), transfusion related acute lung injury (TRALI), and platelet transfusion refractoriness. ### Claim 9 (depends on 6) The method of claim 6, wherein the composition is administered before the subject is administered a blood transfusion, after the subject is administered the blood transfusion, and/or during the blood transfusion. ### Claim 10 (depends on 6) The method of claim 6, wherein the composition comprises at least one pharmaceutically acceptable carrier, diluent, or excipient. ### Claim at position 7 11-13. (canceled) ### Claim 14 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 5. ### Claim 15 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 6. ### Claim 16 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 7. ### Claim 17 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 8. ### Claim 18 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 11. ### Claim 19 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 12. ### Claim 20 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 21. ### Claim 21 (depends on 6) The method of claim 6, wherein the composition comprises a peptide comprising the amino acid sequence of SEQ ID NO: 31.